4 recruiting, 2 not yet recruiting, 1 active not recruiting. 4 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Recruiting 3, Not yet recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow Oligoprogression: new trials by email Literature Review of Oligoprogression trials Research Report on Oligoprogression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy - Oligoprogression, Oligometastatic Disease | Not applicable | Recruiting | British Columbia Cancer Agency | 194 | 2025-12-04 | 2025-12-15 |
| SMC Radiation Oncology SABR Cohort for Oligometastasis Stereotactic body radiotherapy (SBRT) - Stereotactic Body Radiation Therapy (SBRT), Oligometastasis | Recruiting | Samsung Medical Center | 60 | 2025-05-01 | 2025-08-13 | |
| Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression Single fraction SABR, Multiple fraction SABR, QoL reporting alone - Oligometastatic Disease, Oligoprogression | Not applicable | Recruiting | Robert Olson | 598 | 2025-04-16 | 2026-09-24 |
| Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment SBRT and second-line systemic therapy, Second-line systemic therapy - Hepatocellular Carcinoma, Oligoprogression | Phase 2 | Not yet recruiting | Sun Yat-sen University | 70 | 2024-10-01 | 2024-09-19 |
| STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer Stereotactic body radiotherapy - Metastatic Breast Cancer, Oligoprogression | Not applicable | Not yet recruiting | Juravinski Cancer Center | 36 | 2024-09-01 | 2024-07-08 |
| Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation. Hypofractionated SRT (stereotactic radiotherapy), Historical single-dose SRS (stereotactic radiosurgery) - Brain Metastasis, Oligoprogression | Not applicable | Recruiting | Centre Francois Baclesse | 504 | 2023-01-12 | 2026-01-27 |
| Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study Osimertinib, Radiotherapy - NSCLC, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 42 | 2022-01-20 | 2026-01-14 |
Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Neoplasm Metastasis (1)
Neoplasms (4) · Neoplasms by Site (3) · Adenocarcinoma (1) · Brain Diseases (1) · Breast Diseases (1) · Carcinoma (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Liver Diseases (1) · Liver Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1)
Radiosurgery (4) · Health Records, Personal (1) · Radiotherapy (1) · Spermine Synthase (1) · osimertinib (1)
AIO-Studien-gGmbH (1) · British Columbia Cancer Agency (1) · Centre Francois Baclesse (1) · Juravinski Cancer Center (1) · Robert Olson (1) · Samsung Medical Center (1) · Sun Yat-sen University (1)
Canada (2) · France (1) · Germany (1) · Ireland (1) · South Korea (1)
Amanda Tufman, Prof. Dr. (1) · Kyle McGowan (1) · Robert Olson, MD, MSc, FRCPC (1)